Phase 3Completed
Chiglitazar Added to Metformin for Type 2 Diabetes
A Randomised Double-blind Placebo Parallel Controlled Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of Chiglitazar Added to Metformin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy (RECAM)
- Sponsor
- Chipscreen Biosciences, Ltd. (Industry)
- Enrolment
- 533 enrolled
- Conditions
- Type 2 Diabetes
- Interventions
- Chiglitazar 32mg; Chiglitazar 48mg; Placebo; Metformin Hydrochloride
- Ages
- adults, older adults
- Registry
- NCT04807348
Full record on ClinicalTrials.gov
From the registry
The purpose of the trial is to evaluate the effect of Chiglitazar added to metformin to type 2 diabetes Inadequately controlled with metformin Monotherapy.
Primary outcomes
- percentage of HbA1c change from baseline
History
Last registry update
Primary completion
Started
Registered